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infectious diseases' epidemiology and cost-effectiveness of interven-
tions for control, and is increasingly becoming the standard and pre-
ferred approach in this area. As opposed to static modelling, dynamic
modelling explicitly takes transmission of infectious agents into
account, providing the opportunity to, for example, incorporate the in-
direct protective effect of vaccination on non-vaccinated individuals,
i.e. herd protection, in the analysis (Jit and Brisson, 2011). Often, appli-
cation of a dynamic model improves cost-effectiveness outcomes of
infectious diseases control interventions, but in scarce cases detrimental
effects on health, costs and cost-effectiveness might emerge. For exam-
ple, vaccination may shift the age of infection upwards, which may be
associated with increased severity of disease or associations with
other diseasesmay exist (Heininger and Seward, 2006); reﬂecting addi-
tional effects that can be covered within a dynamic approach, next to
herd protection. In this issue, Van Lier et al. (2015) add to such insights
in the context of varicella vaccination, using dynamic modelling. In the
context of modelling herd protection and age shifts, the authors illus-
trate the potentially crucial impact of varicella vaccination on herpes
zoster (HZ) disease.
Varicella zoster virus (VZV) causes chickenpox during initial infec-
tion at childhood age. After resolution of the disease, however, the
virus remains latently present in dorsal root ganglion cells. In later life,
it can reactivate causing HZ. Potential relationship between varicella
vaccination and HZ disease draws on the hypothesis raised by Hope-
Simpson in the 1960s, that contacts between varicella-infected children
and adults cause exogenous boosting of immunity against VZV in the
latter, thus reducing the risk of HZ later in life (Hope-Simpson, 1965).
In other words, childhood varicella vaccination, by eliminating exoge-
nous boosting, might ultimately promote the risk of development of
HZ in the adult population. This hypothesis is not undisputed, nor di-
rectly proven so far, but has received considerable attention. For in-
stance, a recently published study from Ogunjimi et al. modelled that
childhood varicella vaccination might almost double HZ incidence
30 years later (for example, among parents of vaccinated children)
(Ogunjimi et al., 2015). Accordingly, it has been remarked – also by
Van Lier et al. (2015) – that a few generations have to pay with anDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.08.017.
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long run.
In this issue, Van Lier et al. analysed the cost-effectiveness of varicel-
la vaccination in the Netherlands using dynamic modelling with the
Hope-Simpson hypothesis included and excluded (Van Lier et al.,
2015). Considering a lifetime time horizon and discounting according
to the Dutch guidelines for pharmacoeconomic research, the authors
come to a clear and consistent conclusion. Without the Hope-Simpson
hypothesis, varicella vaccination is highly cost-effective or even cost-
savingwithmajor gains of quality-adjusted life years (QALYs). Inclusion
of the boosting hypothesis, however, results in dominance for the no
varicella vaccination policy, because varicella vaccination would result
in higher costs and QALY losses due to an increase of HZ in the adult
population.
Prior to the current study of Van Lier et al., four studies have
analysed the impact of varicella vaccination on HZ using dynamic
modelling (Damm et al., 2015). These studies include investigations of
the issue for surrounding countries of the Netherlands, such as the UK
(van Hoek et al., 2012) and Belgium (Bilcke et al., 2013). Van Lier et al.
support the overall ﬁndings from these earlier studies. Notably, similar
to Van Lier et al., these studies generally found that varicella vaccination
is not cost-effective or even results in net QALY losses when the Hope-
Simpson hypothesis was included in the modelling. Generally, in these
dynamicmodels cost-effectiveness of infant vaccination against varicel-
la is driven by herd protection, related to the possible association with
HZ and age shifts (upwards shift for varicella and potentially down-
wards for HZ). Potential improvement the health-economic proﬁle of
varicella vaccination, suggested by the authors, included targeting of
vaccination to 11-year-old children after anamnesis (Damm et al.,
2015).
Obviously, one solution to overcome the increase of HZ incidence
among adults could be HZ vaccination (Damm et al., 2015; van Hoek
et al., 2012; Bilcke et al., 2013), with highly effective vaccines being
available and further developed. Van Lier et al. argue thatHZvaccination
cannot be motivated from the perspective of its pushing varicella vacci-
nation towards favourable cost-effectiveness. However, we would
argue that HZ vaccination can be highly cost-effective on its own right
and, on this basis, some countries, including theUK, have already imple-
mented HZ vaccination. For the Netherlands, de Boer et al. (2013)
estimated the cost-effectiveness of HZ-vaccination at €29,000–36,000
per QALY gained, depending on the vaccination age. At a cost-the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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well be considered cost-effective, in particular in view of the fact that
even higher thresholds of €80,000 per QALY or beyond apply to
oncological and orphan drugs (Rozenbaum et al., 2010). Notably, the
abovementioned studies for the UK (van Hoek et al., 2012) and
Belgium (Bilcke et al., 2013) also found that combining paediatric vari-
cella vaccination with HZ vaccination of the elderly would be cost-
effective on the long run.
In conclusion, uncertainty on the cost-effectiveness of varicella vac-
cination remains, covering the full spectrum from being cost-saving to
generating QALY losses. A change in this unsatisfactory situation
through novel convincing epidemiological data cannot be expected on
the short term. In the meanwhile, as suggested by Van Lier et al.,
decision-making on implementation of infant varicella vaccination in
national immunization programmes shouldweigh the various scenarios
within this ‘dynamic’ marriage between varicella and zoster, regarding
costs, beneﬁts and likelihoods of these scenarios. Notably, combination
of childhood varicella vaccination with HZ vaccination of the adult
population may reduce the uncertainty and represents a cost-effective
option already per se.
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